Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

Xi Wang; Jing Ni; Chen Long Hsu; Sharlin Johnykutty; Ping Tang; Yuan Soon Ho; Chia Hwa Lee; Shuyuang Yeh

doi:10.3109/07357900802392659

Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

Xi Wang, Jing Ni, Chen Long Hsu, Sharlin Johnykutty, Ping Tang, Yuan Soon Ho, Chia Hwa Lee, Shuyuang Yeh

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.

Original language	English
Pages (from-to)	971-977
Number of pages	7
Journal	Cancer Investigation
Volume	27
Issue number	10
DOIs	https://doi.org/10.3109/07357900802392659
Publication status	Published - Nov 13 2009

Keywords

BCa
TAP

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/07357900802392659

Cite this

@article{c34053a038394c54a74e7e25b4fe99bf,

title = "Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer",

abstract = "We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.",

keywords = "BCa, TAP",

author = "Xi Wang and Jing Ni and Hsu, {Chen Long} and Sharlin Johnykutty and Ping Tang and Ho, {Yuan Soon} and Lee, {Chia Hwa} and Shuyuang Yeh",

year = "2009",

month = nov,

day = "13",

doi = "10.3109/07357900802392659",

language = "English",

volume = "27",

pages = "971--977",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor & Francis Group LLC Philadelphia",

number = "10",

}

TY - JOUR

T1 - Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

AU - Wang, Xi

AU - Ni, Jing

AU - Hsu, Chen Long

AU - Johnykutty, Sharlin

AU - Tang, Ping

AU - Ho, Yuan Soon

AU - Lee, Chia Hwa

AU - Yeh, Shuyuang

PY - 2009/11/13

Y1 - 2009/11/13

N2 - We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.

AB - We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.

KW - BCa

KW - TAP

UR - http://www.scopus.com/inward/record.url?scp=70450212895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450212895&partnerID=8YFLogxK

U2 - 10.3109/07357900802392659

DO - 10.3109/07357900802392659

M3 - Article

AN - SCOPUS:70450212895

SN - 0735-7907

VL - 27

SP - 971

EP - 977

JO - Cancer Investigation

JF - Cancer Investigation

IS - 10

ER -

Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this